OTCMKTS:CRLBF - Cresco Labs Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $23.28
  • Forecasted Upside: 120.85 %
  • Number of Analysts: 8
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 8 Buy Ratings
  • 0 Strong Buy Ratings
$10.54
▼ -0.18 (-1.68%)

This chart shows the closing price for CRLBF by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Cresco Labs Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for CRLBF and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for CRLBF

Analyst Price Target is $23.28
▲ +120.85% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Cresco Labs in the last 3 months. The average price target is $23.28, with a high forecast of $36.00 and a low forecast of $11.00. The average price target represents a 120.85% upside from the last price of $10.54.

This chart shows the closing price for CRLBF for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 8 polled investment analysts is to buy stock in Cresco Labs. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/30/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/29/2020
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
7/28/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
10/26/2020
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 0 sell ratings
1/24/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
4/24/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/23/2021
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/23/2021

Latest Recommendations

  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
7/7/2021Jefferies Financial GroupInitiated CoverageBuy$36.00
6/2/2021BTIG ResearchReiterated RatingBuyC$24.00
3/26/2021Stifel NicolausLower Price TargetBuy$36.00 ➝ $34.00
3/19/2021Stifel NicolausBoost Price TargetBuy$33.50 ➝ $36.00
3/8/2021BTIG ResearchInitiated CoverageBuy
2/25/2021Stifel NicolausBoost Price TargetBuy$21.50 ➝ $33.50
2/18/2021Alliance Global PartnersInitiated CoverageBuy$25.00
1/20/2021Cantor FitzgeraldBoost Price TargetOverweight$18.00 ➝ $21.00
1/18/2021Haywood SecuritiesBoost Price TargetNA$24.00
1/13/2021Canaccord GenuityBoost Price TargetBuy$16.00 ➝ $20.50
11/19/2020Piper SandlerBoost Price TargetOverweight$12.00 ➝ $14.00
11/19/2020Cantor FitzgeraldBoost Price TargetOverweight$16.00 ➝ $18.00
10/30/2020Cantor FitzgeraldBoost Price TargetOverweight$15.00 ➝ $16.00
8/21/2020Roth CapitalBoost Price TargetBuy$8.00 ➝ $11.00
8/21/2020Cantor FitzgeraldBoost Price TargetOverweight$11.00 ➝ $15.00
8/21/2020Piper SandlerBoost Price TargetOverweight$8.00 ➝ $12.00
7/22/2020Stifel NicolausInitiated CoverageBuy$10.00
6/12/2020Needham & Company LLCInitiated CoverageHold$4.20
5/29/2020Canaccord GenuityReiterated RatingBuy$11.50
5/27/2020Cantor FitzgeraldBoost Price TargetOverweight$8.00 ➝ $9.50
4/28/2020Canaccord GenuityLower Price TargetBuy$12.50 ➝ $11.50
4/28/2020Cantor FitzgeraldLower Price TargetOverweight$10.00 ➝ $8.00
3/30/2020Cantor FitzgeraldLower Price TargetOverweight$12.00 ➝ $10.00
2/21/2020LADENBURG THALM/SH SHInitiated CoverageBuy
2/13/2020Cantor FitzgeraldInitiated CoverageOverweight$12.00
12/20/2019Roth CapitalInitiated CoverageBuy$12.00
9/13/2019CowenInitiated CoverageOutperform$14.00
8/12/2019Piper Jaffray CompaniesInitiated CoverageOverweight ➝ Overweight$11.00
6/10/2019Compass PointInitiated CoverageBuy
(Data available from 7/23/2016 forward)
Cresco Labs logo
Cresco Labs Inc., together with its subsidiaries, cultivates, manufactures, and sells retail and medical cannabis products in the United States. It provides cannabis in flowers, vape pens, live resins, disposable pens, and extracts under the Cresco brand; flowers, popcorns, shakes, pre-rolls, and vapes under the High Supply brand; flowers, vapes, and edibles under the Good News brand; vapes and edibles under the Wonder Wellness Co brand; and tinctures, capsules, salves, ingestibles, sublingual oils, and transdermal patches under the Remedi brand, as well as cannabis products made from plants under the Reserve brand. The company also offers cannabis flowers under the FloraCal brand; and chocolate and toffee confections, fruit-forward gummies, hard sweets, and taffy under the Mindy's Edibles brand, as well as licenses the Kiva brand, which produces cannabis infused edibles, including chocolate confections, gummies, mints, and tarts. It owns and operates 32 dispensaries, as well as 44 retail licenses. The company is headquartered in Chicago, Illinois.
Read More

Today's Range

Now: $10.54
Low: $10.20
High: $10.72

50 Day Range

MA: $11.24
Low: $10.29
High: $12.25

52 Week Range

Now: $10.54
Low: $5.05
High: $17.49

Volume

396,295 shs

Average Volume

1,026,743 shs

Market Capitalization

N/A

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Cresco Labs?

The following sell-side analysts have issued stock ratings on Cresco Labs in the last year: Alliance Global Partners, BTIG Research, Canaccord Genuity, Cantor Fitzgerald, Haywood Securities, Jefferies Financial Group Inc., Piper Sandler, Roth Capital, and Stifel Nicolaus.
View the latest analyst ratings for CRLBF.

What is the current price target for Cresco Labs?

9 Wall Street analysts have set twelve-month price targets for Cresco Labs in the last year. Their average twelve-month price target is $23.28, suggesting a possible upside of 120.9%. Jefferies Financial Group Inc. has the highest price target set, predicting CRLBF will reach $36.00 in the next twelve months. Roth Capital has the lowest price target set, forecasting a price of $11.00 for Cresco Labs in the next year.
View the latest price targets for CRLBF.

What is the current consensus analyst rating for Cresco Labs?

Cresco Labs currently has 8 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe CRLBF will outperform the market and that investors should add to their positions of Cresco Labs.
View the latest ratings for CRLBF.

What other companies compete with Cresco Labs?

How do I contact Cresco Labs' investor relations team?

The company's listed phone number is 312-929-0993. The official website for Cresco Labs is www.crescolabs.com.